Phase
Condition
Hiv Infections
Treatment
BIC/F/TAF 50Mg-200Mg-25Mg Tablet
BIKTARVY 50Mg-200Mg-25Mg Tablet
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
At least 18 years old on day of signing informed consent
Positive for human immunodeficiency virus (HIV)
Received a previous renal transplant
Must have controlled HIV infection for at least 3 months prior to enrollment
Exclusion
Exclusion Criteria:
Received a kidney from a donor who was HIV positive (unless a false positive)
Currently taking BIC/F/TAF for treatment of HIV
Has allergies to any of the HIV medications in BIC/F/TAF (bictegravir,emtricitabine, or tenofovir alafenamide)
Currently taking dofetilide or rifampin
Is pregnant or breastfeeding
Study Design
Connect with a study center
Weill Cornell Medicine
New York, New York 10065
United StatesSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.